Vismodegib (GDC-0449) is a potent, small-molecule Smoothened (SMO) antagonist. It affects the Hedgehog (Hh) signaling pathway by binding to the SMO receptor and blocking downstream GLI activation, thereby inhibiting cancer cell proliferation, invasion, and inducing apoptosis.